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Interleukin-1R like receptors (ILRs) andToll Like Receptors (TLRs) are key receptors of innate
immunity, inflammation, and orientation of the adaptive response. They belong to a super-
family characterized by the presence of a conserved intracellular domain, theToll/IL-1R (TIR)
domain, which is involved in the activation of a signaling cascade leading to activation of
transcription factors associated to inflammation.The activation of inflammatory responses
and immunity by ILRs or TLRs signaling is potentially detrimental for the host in acute and
chronic conditions and is tightly regulated at different levels by receptor antagonists, decoy
receptors or signaling molecules, and miRNAs. Recent evidence suggests that the ILRs
family member TIR8 (also known as SIGIRR) is a regulatory protein acting intracellularly to
inhibit ILRs and TLRs signaling. In particular, current evidence suggests that TIR8/SIGIRR
dampensTLRs-mediated activation and inhibits signaling receptor complexes of IL-1 family
members associated withTh1 (IL-18),Th2 (IL-33), andTh17 (IL-1) differentiation. Studies with
Tir8/Sigirr-deficient mice showed that the ability to dampen signaling from ILRs and TLRs
family members makesTIR8/SIGIRR a key regulator of inflammation. Here, we summarize
our current understanding of the structure and function of TIR8/SIGIRR, focusing on its
role in different pathological conditions, ranging from infectious and sterile inflammation,
to autoimmunity and cancer-related inflammation.
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INTRODUCTION
Interleukin-1R like receptors (ILRs) and Toll Like Receptors
(TLRs) are key receptors of innate immunity and inflammation.
They are members of a superfamily of phylogenetically conserved
proteins characterized by the presence of a conserved intracellular
domain, the Toll/IL-1R (TIR) domain (Figure 1).
Upon ligand binding, dimerization of receptor TIR domains,
recruitment of TIR domain containing adapter proteins and
activation of a signaling pathway occur. This pathway involves
Myeloid differentiation factor 88 (MyD88), IL-1R associated
kinases (IRAKs), and tumor necrosis factor receptor-associated
factor 6 (TRAF6) and leads to activation of nuclear factor kappa
B (NF-κB), activator protein-1 (AP-1), c-Jun N-terminal kinase
(JNK),p38 mitogen-associated protein kinase,and members of the
interferon regulatory factor family (O’Neill, 2006, 2008; Dinarello,
2009).
The family is subdivided in TLRs bearing leucine-rich repeats
in the extracellular domain, and ILRs bearing Ig-like domains.
Nowadays, 10 TLRs have been reported in humans and 12 in the
mouse (Kang and Lee, 2011), whereas ILRs family includes 10
proteins. TLRs are receptors for specific pathogen associated mole-
cular patterns (PAMPs) and of necrotic cell-derived danger signals
(DAMPs) and act as sensors for microorganisms and tissue damage
(Cavassani et al., 2008). The ILRs family includes components of
signaling receptor complexes as well as molecules with regulatory
function (IL-1RII and TIR8/SIGIRR). In particular TIR8, so called
because at the time of cloning it was the eighth molecule with a TIR
domain and also known as single immunoglobulin interleukin-1
receptor related molecule (SIGIRR), is a fringe member of the
family with structural features incompatible with conventional
signaling (Li and Qin, 2005; Garlanda et al., 2009; Figure 1).
Interleukin-1R like receptors ligand family includes pro-
inflammatory molecules such as IL-1α and IL-1β (IL-1F1),
IL-18/IL-1F4, IL-36α/IL-1F6, IL-36β/IL-1F8, and IL-36γ/IL-1F9
(Dinarello et al., 2010; Boraschi et al., 2011). Other members of
IL-1 family show anti-inflammatory activity. IL-1 receptor antago-
nist (IL-1Ra)/IL-1F3 binds to IL-1RI inhibiting the recruitment of
IL-1RAcP and compete with IL-1α and IL-1β for receptor binding
(Dinarello, 2000); IL-36Ra binds IL-1Rrp2 antagonizing IL-36α,
IL-36β, and IL-36γ; IL-37 produces anti-inflammatory effects; and
finally IL-33 binds to T1/ST2, recruits IL-1RAcP and induces the
expression of anti-inflammatory cytokines (Schmitz et al., 2005).
Uncontrolled or deregulated activation of ILRs- or TLRs-
dependent inflammatory and immune responses can be
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FIGURE 1 |The IL-1 receptor (ILRs) andToll like receptor (TLRs)
superfamily. Ligands, receptors, adaptors, and extracellular and
intracellular negative regulators are shown. The ILRs family includes the
receptors (IL-1RI, IL-18R, T1/ST2, IL-1Rrp2) and the accessory proteins
(IL-1RAcP) for IL-1, IL-18, IL-33, and other IL-1 family members (IL-36α,
IL-36β, and IL-36γ). IL-1Ra, soluble IL-1RI, IL-36Ra, IL-37, IL-18 binding
protein (IL-18BP), IL-1RII, and TIR8/SIGIRR are negative regulators
acting at different levels, as receptor antagonists, decoy receptors,
scavengers, or dominant negative. TIR8/SIGIRR, TIGIRR-1, and
TIGIRR-2 are still orphan receptors. Microbial moieties (LPS, Poly I:C,
CpG, Flagellin, and others) and necrotic cell-derived danger signals are
the ligands for TLRs.
detrimental for the host and potentially cause tissue damage
and acute or chronic inflammatory disorders. The activation of
inflammatory responses and immunity by ILRs or TLRs signal-
ing is tightly regulated at different levels. For instance, IL-1Ra
and IL-36Ra are polypeptide antagonists for IL-1RI and IL-1Rrp2,
respectively (Towne et al., 2004; Costelloe et al., 2008;Aksentijevich
et al., 2009; Dinarello, 2009; Reddy et al., 2009). Decoy recep-
tors, such as IL-1RII, bind ligands that are no longer available
for the transducing receptors or form dominant negative non-
signaling complexes with AcPs (Mantovani et al., 2001). IRAK-M
and MyD88s are negative regulators of ILRs and TLRs signal-
ing, acting intracellularly (Kobayashi et al., 2002; Janssens et al.,
2003). TIR8/SIGIRR, which will be discussed in detail below,
inhibits the activation of the signaling pathway by TLRs and
IL-1R by interfering with the association of adaptor molecules
to the receptor complex. Finally, a novel level of feedback sys-
tem has been identified, consisting of targeting of ILRs or TLRs
signaling proteins or transcription factors by miRNAs. In particu-
lar, miR-155, miR-21, miR-146a, miR-132, miR-9, and miR-147
have all been significantly implicated in the immune response
initiated by IL-1R or TLRs (Bazzoni et al., 2009; Nahid et al.,
2011; Quinn and O’Neill, 2011). For instance, the induction
of transcription of miR-146a or miR-9 by LPS, tumor necro-
sis factor alpha (TNFα) and IL-1α is dependent on NF-κB,
and in turn, miR-146a potentially targets TRAF6 and IRAK-
1, whereas miR-9 targets the NFkB1 transcript, dampening the
immune response (Bazzoni et al., 2009; Quinn and O’Neill,
2011).
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Here, we summarize our current understanding of the struc-
ture and function of TIR8/SIGIRR, focusing on its regulatory
role in different pathological disorders dependent on ILRs and
TLRs activity, ranging from inflammation in infectious and sterile
conditions, to autoimmunity and cancer-related inflammation.
TIR8/SIGIRR GENE AND PROTEIN
TIR8/SIGIRRis an orphan receptor. The human gene is localized
on chromosome 11, band p15.5, and encompasses 10 exons span-
ning about 11700 bp, whereas the murine gene is localized on
chromosome 7, band F4, and includes nine exons spanning about
4000 bp (Thomassen et al., 1999). The human protein is 410 amino
acid-long and is organized in an extracellular domain compris-
ing of a single Ig domain, in contrast with others ILRs family
members which have three, a transmembrane domain, an intra-
cellular conserved TIR domain, and a peculiar terminal 95 aa long
tail, which is not present in other mammal TIR family members.
Two residues of the TIR domain (Ser447 and Tyr536) consid-
ered necessary for signal transduction of IL-1R1 are replaced by
Cys222 and Leu305 in TIR8/SIGIRR, but the functional relevance
of this replacement has not been addressed. TIR8/SIGIRR is exten-
sively N - and O-glycosylated. Indeed five potential N -glycosylated
sites in human and four in mouse are present in the extracellu-
lar portion of the molecule (Thomassen et al., 1999; Lech et al.,
2007).
TIR8/SIGIRR shows a conserved sequence and pattern of
expression among vertebrates, from chicken to humans (Riva
et al., 2009). In particular, protein sequences of human and mouse
TIR8/SIGIRR are 82% identical.
Little is known about TIR8/SIGIRR phylogenetic evolution, but
the recent discovery in teleost fish of DIGIRR is helpful in defining
the evolutionary history of TIR family members. DIGIRR presents
two Ig-like domains in its extracellular region, a Arg-Tyr-mutated
TIR domain and a unique expression within the Golgi appara-
tus. In vitro experiments demonstrate that DIGIRR is a negative
regulator of LPS and IL-1β-mediated NF-κB activation (Gu et al.,
2011). The authors suggest that DIGIRR could represent a “tran-
sitional molecule” between a potent receptor such as IL-1R1 and a
negative regulator such as TIR8/SIGIRR.
TIR8/SIGIRR is ubiquitously expresses in tissues, in particu-
lar in kidney, digestive tract, liver, lung, and lymphoid organs
(Thomassen et al., 1999; Polentarutti et al., 2003). Particularly,
in kidney it is expressed on the luminal border and basolateral
membrane of proximal tubular cells (Polentarutti et al., 2003;
Lech et al., 2007), in the intestinal tract by epithelial cells and
in lymphatic organs by NK cells, B lymphocytes, monocytes, and
immature dendritic cells (DCs)(Polentarutti et al., 2003; Garlanda
et al., 2004; Lech et al., 2007; Xiao et al., 2007), in the lung by
bronchial epithelium, blood endothelial cells, and leukocytes (Veliz
Rodriguez et al., 2012).
Mechanisms of regulation of TIR8/SIGIRR expression are still
poorly defined (Table 1).
Kodota et al. recently showed that TIR8/SIGIRR proximal
promoter presents a binding site for the transcription factor
SP1, a zinc finger proteins, which binds directly to DNA and
enhances TIR8/SIGIRR gene transcription. In the presence of
LPS, SP1 binding to TIR8/SIGIRR promoter consensus sites was
reduced, and consequently TIR8/SIGIRR expression was tran-
siently inhibited in epithelial cells (Kadota et al., 2010). These
data potentially explain previous findings showing that human
and murine TIR8/SIGIRR expression was usually found down-
regulated by LPS stimulation or in other inflammatory conditions
compared to homeostatic conditions (Polentarutti et al., 2003;
Wald et al., 2003; Huang et al., 2006). For instance, ulcerative col-
itis in human and colitis in mouse were associated with reduced
TIR8/SIGIRR expression by epithelial cells (Kadota et al., 2010).
Bacterial infection of intestinal epithelial cells and exposure to
flagellin transiently decreased TIR8/SIGIRR protein expression.
Conversely, stable overexpression of TIR8/SIGIRR diminished NF-
κB–mediated IL-8 responses to TLRs ligands (Khan et al., 2010).
In psoriatic patients peripheral blood cells expressed decreased
levels of TIR8/SIGIRR and other anti-inflammatory molecules
Table 1 | Regulation ofTIR8/SIGIRR expression.
Stimuli Organism Cell type mRNA/protein Reference
UPREGULATION
Th2-polarization Mouse T lymphocytes Protein Bulek et al. (2009)
Vasoactive intestinal peptide Mouse Macrophages and langerhans cells mRNA Jiang et al. (2012)
LPS Mouse Payer’s patch DCs mRNA Davies et al. (2010)
DOWNREGULATION
LPS Mouse and human Epithelial cells, DC, monocytes,
polymorphonuclear granulocytes
mRNA, protein Polentarutti et al. (2003), Wald et al.
(2003), Huang et al. (2006), Garlanda
et al. (2004), Kadota et al. (2010)
Flagellin, bacterial infection Mouse and human Intestinal epithelial cells Protein Khan et al. (2010)
Psoriatic arthritis Human Peripheral blood leukocytes mRNA Batliwalla et al. (2005)
Necrotizing enterocolitis Human Fetal enterocytes mRNA Nanthakumar et al. (2011)
Asymptomatic bacteriuria Human Neutrophil polymorphonuclear
granulocytes
Protein Ragnarsdottir et al. (2007)
P. aeruginosa acute lung infection Mouse Respiratory epithelium,
polymorphonuclear granulocytes
mRNA Veliz Rodriguez et al. (2012)
Toxoplasma gondii Mouse Intestinal epithelial cells mRNA Gopal et al. (2008)
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(Batliwalla et al., 2005). Nanthakumar et al. (2011) demonstrated
that TIR8/SIGIRR, together with other anti-inflammatory genes,
was expressed at low levels in fetal human enterocytes and at
lower levels in necrotizing enterocolitis intestinal cells, whereas
pro-inflammatory genes were present at high levels, potentially
explaining the excessive inflammatory response of the imma-
ture intestine. In asymptomatic bacteriuria patients, TIR8/SIGIRR
and TLR4 expression were significantly lower than in the age-
matched control subjects (Ragnarsdottir et al., 2007). In mouse,
Tir8/Sigirr mRNA was down-regulated upon acute lung infec-
tion by Pseudomonas aeruginosa in the lung and in neutrophils
(Veliz Rodriguez et al., 2012) or in intestinal epithelial cells upon
Toxoplasma gondii (Gopal et al., 2008). However, Adib-Conquy
et al. (2006) reported that human monocytes up-regulated the
TIR8/SIGIRR transcript during sepsis and sterile systemic inflam-
mation, which was associated to reduced TNFα and enhanced
IL-10 production in response to LPS and Pam3CysSK4.
Stimuli inducing TIR8/SIGIRR expression are not well defined
yet and mechanisms involved are not known. In T lympho-
cytes, Th2-polarization induced higher levels of TIR8/SIGIRR
expression than Th1-polarization or non-differentiating condi-
tions (Bulek et al., 2009). The neuropeptide vasoactive intesti-
nal peptide (VIP) was found to up-regulate Tir8/Sigirr in
a cAMP-independent manner in the cornea of P. aeruginosa
infected mice as well as in macrophages and Langerhans cells
(Jiang et al., 2012). Recently, the probiotic microorganism Lac-
tobacillus jensenii was found to up-regulate TIR8/SIGIRR, A20,
and IRAK-M in porcine Payer’s patch antigen presenting cells
through TLR2, and to increase the expression of IL-10 and
TGF-β thus inducing tolerogenic properties (Villena et al.,
2012).
Finally, in vitro and in vivo experiments showed that LPS-
induced up-regulation of Tir8/Sigirr, tollip, and T1/ST2 messenger
RNA in murine Payer’s patch DCs, but not in spleen DCs, suggest-
ing that Payer’s patch DCs use these molecules in their arsenal to
prevent the initiation of TLRs signaling (Davies et al., 2010).
REGULATION OF ILRs AND TLRs SIGNALING BY TIR8/SIGIRR
TIR8/SIGIRR lacks a specific ligand, even if it was demon-
strated that glial cell TIR8/SIGIRR interacts with IL-36Ra regu-
lating inflammatory response in the brain (Costelloe et al., 2008).
TIR8/SIGIRR inhibits NF-κB and JNK activation dependent on
ILRs or TLRs family member activation, but not TNFα-dependent
NF-κB activation or IFNγ-dependent STAT1 activation (Wald
et al., 2003; Garlanda et al., 2004). The inhibitory activity is exerted
on IL-1RI, IL-18R, T1/ST2, TLR4, TLR7, and TLR9 (Wald et al.,
2003; Garlanda et al., 2004; Qin et al., 2005; Lech et al., 2007,
2008; Bulek et al., 2009). TIR8/SIGIRR regulates also TLR3 and
TLR1/2-dependent signaling in kidney monocytes (Lech et al.,
2007; Figure 2).
Little is known about the interaction between TIR8/SIGIRR
and other members of the superfamily and the data are sometimes
contradictory. This could be explained by specific expression of
TIR8/SIGIRR or other receptor complex components in different
cell types or by posttranscriptional modifications, such as glycosy-
lation, that modify biological function of TIR8/SIGIRR (Garlanda
et al., 2004).
It has been proposed that the extracellular Ig-like domain of
TIR8/SIGIRR interferes with the dimerization of IL-1RI and IL-
1RAcP. In addition, the TIR8/SIGIRR cytoplasmic TIR domain
sequesters proximal TIR-containing adaptor molecules, such as
IRAK and TRAF6 after IL-1 stimulation. Mutagenesis studies
showed that only the TIR domain (excluding the C-tail part) was
necessary for TIR8/SIGIRR to inhibit TLR4 signaling (Wald et al.,
2003; Qin et al., 2005). In contrast, T1/ST2 interacts with both
TIR8/SIGIRR extracellular and intracellular domains, even if the
TIR domain is crucial for TIR8/SIGIRR activity (Bulek et al., 2009).
Gong et al. (2010) addressed by a computational approach the
molecular mechanism for the interaction of TIR8/SIGIRR and
TLR4 or TLR7 and constructed a three-dimensional model for
the TLR4, TLR7, MyD88, and TIR8/SIGIRR TIR domains. Recep-
tor activation would trigger the formation of TLR4 and TLR7
TIR dimers recruiting MyD88 TIR dimers resulting in a signal-
ing tetramer, in line with previous data (Loiarro et al., 2005;
Nunez Miguel et al., 2007). The model proposed revealed that
TIR8/SIGIRR binds through its BB-loop region to TLR4 and
TLR7 by occupying their self-interacting sites and that the proper
shape and electric environment of the MyD88-binding pocket
are completely disturbed. In addition, TIR8/SIGIRR replaces a
MyD88 monomer, interrupting the MyD88 homodimer forma-
tion (Gong et al., 2010). The BB-loop region is highly conserved
in TIR-containing molecules and plays a crucial role in dimer
formation (Gay et al., 2011). Thus, the interference exerted by
TIR8/SIGIRRBB-loop region prevents the dimerization of the
components of the receptor complex (receptor, accessory pro-
tein and adapter molecule), abolishing the signal transduction. In
contrast, TIR8/SIGIRR unique C-tail is distant from the active BB-
loop, consistent with the observation that this tail is not required
for TIR8/SIGIRR inhibitory effect on TLRs signaling (Qin et al.,
2005).
TIR8/SIGIRR also modulates IL-1-induced phosphorylation
of JNK and mTOR kinase in Th17 lymphocytes, playing a non-
redundant role in controlling mTOR-dependent Th17 differenti-
ation, proliferation, and cytokine production (Gulen et al., 2010).
On the same line, TIR8/SIGIRR was found to regulate IL-1- or
commensal-TLRs-dependent activation of the Akt-mTOR axis
in intestinal epithelial cells. The Akt-mTOR axis promotes cycle
progression through its impact on posttranscriptional control of
key cell cycle regulators and consequent genetic instability (Xiao
et al., 2010; Figure 2). These findings open a new scenario for
TIR8/SIGIRR acting as a modulator of autoimmune diseases and
as tumorigenesis suppressor (see below).
ROLE OF TIR8/SIGIRR IN INFECTION-DEPENDENT
INFLAMMATION
In different infectious conditions, TIR8/SIGIRR emerged as a non-
redundant molecule involved in dampening inflammation and tis-
sue damage by controlling TLRs-, but in particular ILRs-induced
inflammatory response to pathogens (Figure 3; Table 2).
In Mycobacterium tuberculosis lung infection, Tir8/Sigirr-
deficient mice showed exaggerated susceptibility to mortality,
associated to overwhelming systemic inflammatory response,
despite there was no difference in tissue bacterial load compared
to control mice (Garlanda et al., 2007a). Indeed, treatment of
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FIGURE 2 | Regulatory function ofTIR8/SIGIRR in signaling. TIR8/SIGIRR
is a receptor composed by a single extracellular Ig domain (amino acids
17–112), a transmembrane domain (amino acids 117–139); an intracellular
conserved TIR domain (amino acids 166–305), and a 95 amino acid-long
intracellular tail. Two conserved amino acid (Ser, Tyr in TIR domain) necessary
for IL-1R-signaling are replaced in TIR8/SIGIRR (Cys 222, Leu 305) potentially
leading to a non-conventional activation. TIR8/SIGIRR is an orphan receptor,
but IL-36Ra has been proposed as a TIR8/SIGIRR ligand in glial cells.
TIR8/SIGIRR inhibits ILR (IL-1RI, IL-18R, T1/ST2) and TLR (TLR2, TLR3, TLR4,
TLR5, TLR7/8, TLR9, and possibly others) signaling and NF-κB activation. In T
cells and epithelial cells, TIR8/SIGIRR inhibits IL-1-dependent activation of the
Akt-mTOR pathway and of JNK.
Tir8/Sigirr-deficient mice with blocking anti-IL-1 and anti-TNFα
antibodies during M. tuberculosis infection significantly prolonged
survival (Garlanda et al., 2007a).
In Candida albicans or Aspergillus fumigatus infections,
Tir8/Sigirr-deficient mice showed increased susceptibility to
mucosal and disseminated or lung infections, respectively, in terms
of mortality and fungal burden, which were associated to increased
IL-1 signaling and heightened Th17 cell response (Bozza et al.,
2008). The IL-17 pathway plays an important role in the protective
antifungal host defense (Van De Veerdonk et al., 2011), however,
rigorous control of the inflammatory Th17 response is necessary
to prevent immunopathology (Park et al., 2005; Zelante et al.,
2007). Thus, Tir8/Sigirr-deficient mice phenotype was possibly
dependent on IL-1-mediated deregulated Th17 responses.
In a model of keratitis induced by P. aeruginosa, TIR8/SIGIRR
was involved in down-regulating Th1 immunity and associated
IL-1RI and TLR4-activation, thus preventing tissue damage and
promoting resistance to infection (Huang et al., 2006). On the
same line, in acute lung infections caused by P. aeruginosa, a
Gram-negative pathogen responsible of life-threatening infections
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FIGURE 3 | Regulatory function ofTIR8/SIGIRR in pathology.
TIR8/SIGIRR inhibits ILR (IL-1RI, IL-18R, T1/ST2) and TLR (TLR4, TLR7, TLR9,
and possibly others) signaling and NF-κB activation. Gene-targeted mice
demonstrate that Tir8/Sigirr acts as a non-redundant negative regulator
in vivo in different inflammatory conditions dependent on ILR and TLR
activation. For some of these, the pathway prominently regulated by
TIR8/SIGIRR and playing a relevant role in the pathogenesis of the disease
has been defined. For instance, in autoimmunity (EAE) TIR8/SIGIRR
regulates IL-1-dependent Th17 cell differentiation, survival, and
proliferation; in asthma TIR8/SIGIRR regulates the IL-33/ST2 pathway and
Th2 responses; in models of infections (Candida albicans, Aspergillus
fumigatus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa)
TIR8/SIGIRR regulates IL-1RI signaling controlling Th17 and Treg responses
(fungal infections) and pro-inflammatory cytokine production (bacterial
infections). In colitis-associated colon cancer, TIR8/SIGIRR plays a major
role in controlling microbial flora-dependent activation of TLRs, but the
control on ILRs-dependent inflammation can not be excluded. In other
contexts (chronic lymphocytic leukemia, arthritis, kidney transplantation,
and brain inflammation), the molecular pathway regulated by TIR8/SIGIRR
remains to be addressed.
in immunocompromised individuals and cystic fibrosis patients,
Tir8/Sigirr-deficiency was associated to increased susceptibility
in terms of mortality and bacterial load, and to exacerbated
local and systemic production of pro-inflammatory cytokines and
chemokines. IL-1RI-deficiency rescued the phenotype observed in
Tir8/Sigirr-deficient mice. This suggests the non-redundant role
of TIR8/SIGIRR in negatively regulating IL-1RI signaling, which
plays a major role in the pathogenesis of P. aeruginosa infection
(Veliz Rodriguez et al., 2012).
Thus, in both tuberculosis, Candida, and P. aeruginosa infec-
tions, the major protective role identified for TIR8/SIGIRR was
the suppression of excessive IL-1-dependent inflammatory pathol-
ogy, since inhibition of IL-1-signaling was sufficient to rescue the
phenotype of Tir8/Sigirr-deficient mice in these infections.
In dextran sodium sulfate (DSS) colitis model, Tir8/Sigirr-
deficient mice exhibited a dramatic intestinal inflammation com-
pared to wild type mice in terms of weight loss, intestinal bleed-
ing, local tissue damage, and mortality, which was associated to
increased leukocyte infiltration and pro-inflammatory cytokine,
chemokine, and prostaglandin production (Garlanda et al., 2004;
Xiao et al., 2007). In homeostatic conditions, TIR8/SIGIRR was
described to be involved in controlling gut homeostasis. Indeed,
TLRs signaling activated by commensal gut microflora provides
the survival signal for intestinal epithelial cells (Rakoff-Nahoum
et al., 2004; Karin et al., 2006), and Tir8/Sigirr-deficiency was asso-
ciated to increased proliferation in colon crypts and decreased
apoptosis (Xiao et al., 2007). Tir8/Sigirr-deficient colon epithe-
lial cells revealed constitutive NF-κB and JNK activation and
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Table 2 | Regulatory functions ofTIR8/SIGIRR in disease.
Reference
INFECTION-DEPENDENT INFLAMMATION
Mycobacterium tuberculosis lung infection Garlanda et al. (2007a)
Mucosal and disseminated Candida albicans infections Bozza et al. (2008)
Aspergillus fumigatus lung infections Bozza et al. (2008)
Pseudomonas aeruginosa keratitis Huang et al. (2006)
Pseudomonas aeruginosa lung infection Veliz Rodriguez et al. (2012)
Dextran sodium sulfate (DSS) colitis model Garlanda et al. (2004), Xiao et al. (2007)
Survival to endotoxin Wald et al. (2003)
LPS-dependent acute lung injury Chen et al. (2011)
AUTOIMMUNE DISEASES AND ALLERGY
Experimental autoimmune encephalomyelitis (EAE) Gulen et al. (2010)
Systemic lupus erythematosus(lpr and pristane models) Lech et al. (2008, 2010)
Rheumatoid arthritis Drexler et al. (2010)
OVA-induced allergic pulmonary inflammation Bulek et al. (2009)
KIDNEY STERILE INFLAMMATION
Postischemic acute renal failure Lech et al. (2009)
Kidney transplantation Noris et al. (2009)
BRAIN INFLAMMATION
LPS-dependent sickness behavior and age-related neuroinflammation Watson et al. (2010)
Cognitive and synaptic functions Costelloe et al. (2008), Costello et al. (2011)
CANCER
Colitis-associated cancer (AOM/DSS model) Garlanda et al. (2007b), Xiao et al. (2007)
Spontaneous intestinal cancer (Apcmin/+ model) Xiao et al. (2010)
Chronic lymphocytic leukemia (TCL1 transgenic mouse model) Bertilaccio et al. (2011)
up-regulated expression of Cyclin D1 and Bcl-xL, which were fur-
ther increased by treatment with IL-1 or LPS and returned to
the control level after depletion of the commensal bacteria (Xiao
et al., 2007). This spontaneous phenotype was not confirmed in
other studies (Garlanda et al., 2004, 2007b), possibly a reflection
of animal house-dependent variation in microbiota.
Finally, after endotoxin challenge, survival was reduced in
Tir8/Sigirr-deficient mice on a BALB/c background (Wald et al.,
2003), and overexpression of Tir8/Sigirr in lung epithelial cells
suppressed the inflammatory reaction and improved the sur-
vival of BALB/c mice in a model of LPS-dependent Acute Lung
Injury (Chen et al., 2011). However, Tir8/Sigirr-deficient mice on
a C57BL/6× 129/Sv background showed normal systemic or local
inflammatory reactions to LPS (Garlanda et al., 2004).
The relevance in human of data obtained in mice is supported
by a recent genetic analysis suggesting for the first time associa-
tions of TIR8/SIGIRR gene region SNPs with susceptibility to an
infectious disease, in particular with the development of both pul-
monary tuberculosis and tuberculous meningitis in independent
cohorts of Vietnamese subjects (Horne et al., 2012).
ROLE OF TIR8/SIGIRR IN AUTOIMMUNE DISEASES AND
ALLERGY
Members of the ILRs family have emerged as key players in T cell
polarization (Schmitz et al., 2005; Acosta-Rodriguez et al., 2007).
In particular, IL-1 has been identified as a critical factor in the
differentiation and activation of Th17 cells, which mediate the
development of autoimmune and inflammatory diseases, such as
rheumatoid arthritis (RA), systemic lupus erythematosus, mul-
tiple sclerosis, psoriasis, and inflammatory bowel disease (IBD;
Mills, 2011); whereas, IL-33 has been implicated in the initiation
and propagation of Th2 immune responses, involved in allergy
and asthma (Lloyd, 2010).
Gulen et al. (2010) recently showed that TIR8/SIGIRR was
induced during Th17 cell differentiation and that it suppressed
Th17 cell differentiation, proliferation, and cytokine produc-
tion. TIR8/SIGIRR was shown to act through direct inhibition
of multiple IL-1-dependent signaling pathways in T cells, in
particular mTOR, a key transcription factor in IL-1-dependent
Th17 cell proliferation. TIR8/SIGIRR suppressed IL-1 signaling
during initial differentiation of Th17 cells as well as in differ-
entiated effector Th17 cells, acting as key regulator to prevent
overactivation of Th17 cell-mediated pathogenic effects. Indeed,
regulation of IL-1R-mTOR pathway of Th17 development and
activation by TIR8/SIGIRR was critical for the control of Th17 cell-
dependent development of central nervous system (CNS) autoim-
mune inflammation (Figure 3; Table 2). In the absence of this IL-1
regulatory mechanism, Tir8/Sigirr-deficient mice were more sus-
ceptible to experimental autoimmune encephalomyelitis (EAE)
resulting from hyperactivation of Th17 cells upon immunization
with myelin oligodendrocyte glycoprotein (MOG) peptide, which
infiltrated the CNS in greater numbers and showed enhanced path-
ogenic functions compared to wild type Th17 cells (Gulen et al.,
2010).
In addition to IL-1 signaling in Th17 cells, TLRs signal-
ing in innate immune cells, antigen presenting cells, and T
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cells plays a pathogenetic mechanism in different autoimmune
diseases (Mills, 2011). In particular, immune complexes contain-
ing the lupus autoantigen U1snRNP or nucleosomes activate DCs
and autoreactive B-cells via TLR7 and TLR9, respectively, con-
tributing in this way to pathogenesis of systemic lupus erythe-
matosus (Leadbetter et al., 2002; Marshak-Rothstein and Rifkin,
2007). Genetic approaches showed that Tir8/Sigirr-deficiency
alone did not induce autoimmunity against DNA, however, the
deficiency of Tir8/Sigirr in C57BL/6lpr/lpr mice, which develop
delayed autoimmunity due to impaired Fas-induced apoptosis of
autoreactive B and T cells, caused massive lymphoproliferation,
peribronchial inflammation and mesangioproliferative glomeru-
lonephritis (Lech et al., 2008). This autoimmune tissue damage
was associated with increased production of autoantibodies (anti-
dsDNAIgG, anti-nucleosome, anti-Sm antigen, anti-snRNP, and
rheumatoid factor) and early development of hypergammaglob-
ulinemia. Tir8-deficient lpr/lpr mice showed enhanced activation
of DCs to complexed lupus autoantigens, increased production of
pro-inflammatory cytokines (e.g., CCL2, IL-6, and IL-12p40) and
B-cell survival factors (e.g., Baff/BlyS and Bcl-2), increased B cell
proliferation upon exposure to RNA and DNA immune complexes
and other TLRs agonists, and production of lupus autoantibodies.
Thus, the pathogenetic mechanisms underlying the susceptibility
of Tir8/Sigirr-deficient mice in lupus include increased activation
of antigen presenting cells that handle autoantigens, proliferation
of autoreactive B lymphocytes, and production of immunoreg-
ulatory factors. On the same line, Tir8/Sigirr-deficiency caused
increased susceptibility to lupus nephritis in a model, which mim-
ics environmentally induced autoimmunity: intraperitoneal injec-
tion of hydrocarbon oil (pristane) causes persistent abundance
of apoptotic peritoneal cells, chronic granulomatous peritonitis,
ectopic lymphoid tissue formation, and evolution of antinuclear
antibodies, immune complex disease, and lupus nephritis. In this
model, a major pathogenetic role is played by TLR7 signaling
and type I interferon (Savarese et al., 2008). Tir8/Sigirr pro-
tected from hydrocarbon oil-induced lupus by suppressing the
TLR7-mediated activation of DCs and expansion of IgG and
RNA autoreactive lymphocyte clones (Lech et al., 2010). Structure
model prediction identified the BB-loop of TIR8/SIGIRR intra-
cellular TIR domain to interact with TLR7 and MyD88 (Gong
et al., 2010) and indeed, BB-loop deletion was sufficient to com-
pletely abrogate TIR8/SIGIRR inhibitory effect on TLR7 signaling
in DCs (Lech et al., 2010). The relevance of genetic variants of
the TIR8/SIGIRR gene in susceptibility to SLE was recently inves-
tigated in a large European-descent population, but the analysis
was restricted to a single missense polymorphism (rs3210908),
which results in the replacement of a glutamine (Gln) for arginine
(Arg) at amino acid 312 (Q312R) and it did not reveal any associ-
ation between TIR8/SIGIRR gene variants and SLE (Sanchez et al.,
2012).
Increasing evidence implicate TLRs signaling also in RA (Sacre
et al., 2007; Abdollahi-Roodsaz et al., 2009; Drexler and Foxwell,
2010). Overexpression of TIR8/SIGIRR in RA synovial cells led to a
significant inhibition of spontaneous release of pro-inflammatory
mediators, suggesting that either ILRs and/or TLRs signaling was
at least partly responsible for the chronic production of those
mediators in RA (Drexler et al., 2010). The role of TIR8/SIGIRR
as an inhibitor of inflammation was confirmed in vivo, since
Tir8/Sigirr-deficient mice developed a more severe disease in both
the zymosan-induced arthritis and collagen antibody-induced
arthritis models, which was due to increased cellular infiltration
into the affected joints (Drexler et al., 2010). IL-1 plays a signifi-
cant role in zymosan-induced arthritis model, and IL-1Ra reduced
the disease severity in Tir8/Sigirr-deficient mice, but did not com-
pletely rescued the phenotype, suggesting that additional factors,
including TLRs ligands, are driving pathology and are under
Tir8/Sigirr control (Figure 3; Table 2). In agreement with this
study, a gene expression study showed that TIR8/SIGIRR was one
among the genes with the most significantly reduced expression
in peripheral blood cells of patients with psoriatic arthritis com-
pared to control subjects. TIR8/SIGIRR clustered with other genes
involved in downregulation or suppression of innate and acquired
immune responses, suggesting inappropriate control that favors
pro-inflammatory responses (Batliwalla et al., 2005).
T1/ST2, the receptor of IL-33 preferentially expressed in Th2
cells, is a further ILRs controlled by TIR8/SIGIRR. IL-33 plays
a major role in Th2 responses by inducing Th2 cytokines IL-
4, IL-5, IL-13, splenomegaly, eosinophilia, and allergy (Schmitz
et al., 2005). TIR8/SIGIRR was shown tobe expressed during Th2-
polarization and to inhibit IL-33-and T1/ST2-mediated signaling
and Th2 cytokine (IL-4, IL-5, and IL-13) production in vitro
and in vivo (Bulek et al., 2009). Indeed, Tir8/Sigirr-deficient mice
showed hyper responsiveness to IL-33 with increased serum lev-
els of IL-5 and IL-13, splenomegaly, lung inflammation, and
exacerbated Th2 responses in OVA-induced allergic pulmonary
inflammation. These results indicate that Tir8/Sigirr serves as a
negative feedback control in Th2-polarization and restimulation,
thus controlling allergic inflammatory responses (Bulek et al.,
2009; Figure 3; Table 2). However, a genetic analysis performed
on about 850 asthma patients and 640 healthy subjects failed
to identify any association between 12 TIR8/SIGIRR polymor-
phisms or haplotypes identified in this Japanese population with
asthma susceptibility or asthma-related phenotype (Nakashima
et al., 2006).
ROLE OF TIR8/SIGIRR IN KIDNEY STERILE INFLAMMATION
Among solid organs and tissues, TIR8/SIGIRR is highly expressed
in the kidney, in particular by tubular epithelial cells, DCs, and
macrophages, but functional activity of TIR8/SIGIRR in sup-
pressing TLRs-induced expression of pro-inflammatory cytokines
has been demonstrated in renal immune cells but not in renal
parenchymal cells (Lech et al., 2007). The relevance in pathology of
TIR8/SIGIRR expression in kidney has been demonstrated in dif-
ferent conditions, such as lupus nephritis (Lech et al., 2008, 2010;
discussed above) and postischemic acute renal failure or kidney
transplantation (Lech et al., 2009; Noris et al., 2009), conditions
associated to TLRs activation by nucleosomes and DAMPs released
during ischemic cell necrosis, respectively (Figure 3; Table 2).
Postischemic acute renal failure represents a state of sterile
inflammation, in which DAMPs activate innate immune elements,
mostly neutrophils and macrophages, which rather enhances the
subsequent tissue injury than promoting the healing phase, in
particular through TLR4 and TLR2 (Leemans et al., 2005). In a
postischemic renal failure model, intrarenal DCs or macrophages
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were excessively activated in Tir8/Sigirr-deficient mice (Lech et al.,
2009). Hyper activation of myeloid cells increased intrarenal
cytokine and chemokine production and consequently, leukocyte
recruitment, and renal injury. Renal ischemia/reperfusion stud-
ies with chimeric mice confirmed the primary role of Tir8/Sigirr
in suppression of hematopoietic cell activation as compared to
tubular epithelial cell, since lack of Tir8/Sigirr in hematopoietic
cells largely reproduced the phenotype of renal IR injury seen in
Tir8/Sigirr-deficient mice.
In the same line, Noris et al. (2009) showed that the early
post transplant kidney inflammatory response was more severe
in Tir8/Sigirr-deficient grafts, as shown by increased numbers of
infiltrating neutrophils and macrophages and higher TNFα and
chemokine expression, and was followed by an amplified adaptive
immune response against donor antigens, so that acute allograft
rejection occurred within 7–10 days after transplantation. Indeed,
the lack of Tir8/Sigirr in the kidney graft led to amplification of
all downstream effects of ischemia/reperfusion-induced TLRs/IL-
1R-dependent inflammation in the graft. The expansion and mat-
uration of DCs in the graft, Th1 T cell priming, and block of Treg
development finally resulted in acute rejection, thus demonstrat-
ing a role for renal Tir8/Sigirr as a first-line regulation of allogeneic
immune response in situ (Noris et al., 2009).
In contrast, lack of Tir8/Sigirr did not affect the intrarenal
mRNA expression of pro-inflammatory chemokines, profibrotic
mediators, or markers of renal fibrosis after unilateral ureter
obstruction, nor the number of intrarenal macrophages and
myofibroblasts or tissue remodeling in post obstructive kidneys
(Skuginna et al., 2011). These results are in agreement with
data showing that TLR2-, TLR9-, and MyD88-signaling do not
significantly contribute to this model (Chowdhury et al., 2010).
ROLE OF TIR8/SIGIRR IN BRAIN INFLAMMATION
TIR8/SIGIRR is also present in brain (Polentarutti et al., 2003;
Costelloe et al., 2008) where it is expressed on neurons, microglia,
and astrocytes (Andre et al., 2005).
TIR8 was shown to play a functional role in suppressing
microglial activation by LPS and overexpression of CD40 and
ICAM-1 or the production of TNFα, IL-6, and other pro-
inflammatory mediators, both in vitro and in vivo, in hippocampal
tissue. The effect of LPS on exploratory behavior, the so called
sickness behavior, as well as age-related neuroinflammation were
also accentuated in Tir8/Sigirr-deficient mice and were associ-
ated with increased hippocampal expression of CD14 and TLR4,
and NF-κB activation (Watson et al., 2010). In addition, in the
absence of any external inflammatory stimulus, cognitive, and
synaptic functions, such as novel object recognition, spatial refer-
ence memory, and long-term potentiation (LTP), were defective in
Tir8/Sigirr-deficient mice and were associated with up-regulation
of IL-1RI- and TLR4-mediated signal transduction in hippocam-
pus (Costello et al., 2011; Table 2). IL-1ra, an anti-TLR4 antibody,
and also the inhibition of JNK and NF-κB restored the decrease
in synaptic functions in Tir8/Sigirr-deficient mice, demonstrat-
ing the key role of IL-1RI-and TLR4-activation by IL-1α and high
mobility group box 1 (HMGB1), respectively, in this model. These
findings highlighted the functional role of Tir8/Sigirr in regulat-
ing inflammatory mediated synaptic and cognitive decline, and
described evidence of the key role of HMGB1 in this process
(Costello et al., 2011).
Finally, it has been suggested that IL-36Ra has anti-
inflammatory effects in the brain since it abrogated IL-1 and LPS-
induced inflammatory responses specifically in glial cells and IL-1-
or LPS-induced inhibition of LTP and the associated increase in IL-
1β concentration. These effects of IL-36Ra depended on IL-4 pro-
duction and were absent in mixed glia prepared from Tir8/Sigirr-
deficient mice, suggesting that the anti-inflammatory effects of this
cytokine are mediated, at least in part, by TIR8/SIGIRR (Costelloe
et al., 2008).
ROLE OF TIR8/SIGIRR IN INTESTINAL CANCER
The connection between cancer and inflammation is well rec-
ognized in tumors epidemiologically linked to inflammatory
processes. In addition, an inflammatory component is present in
the microenvironment of most neoplastic tissues and includes the
infiltration of white blood cells, prominently tumor-associated
macrophages (TAM); the presence of inflammatory cytokines
(e.g., TNFα, IL-1, IL-6, IL-23, IL-17, chemokines, such as CCL2);
the occurrence of tissue remodeling and angiogenesis (Manto-
vani et al., 2008; Colotta et al., 2009; Biswas and Mantovani, 2010;
Ben-Neriah and Karin, 2011). Two pathways link inflammation
and cancer: in the intrinsic pathway, activation of different classes
of oncogenes drives the expression of inflammation-related pro-
grams, which guide the construction of an inflammatory microen-
vironment, whereas in the extrinsic pathway, inflammatory condi-
tions promote cancer development (e.g., colitis-associated cancer
(CAC) of the intestine; Colotta et al., 2009). NF-κB is one of the
key orchestrators of cancer-related inflammation (Ben-Neriah and
Karin, 2011).
TIR8/SIGIRR was therefore a candidate player potentially
involved in cancer-related inflammation and was first studied in a
model of CAC, a colorectal disease that arises in patients suffering
from chronic IBD, in particular Ulcerative Colitis. In the model
of CAC induced by the pro-carcinogen Azoxymethane (AOM),
followed by exposure to DSS, which causes chronic inflamma-
tion, Tir8/Sigirr-deficient mice exhibited increased susceptibility
to intestinal carcinogenesis, in terms of number, size, and severity
of lesions, in agreement with the increased susceptibility to inflam-
mation (Garlanda et al., 2007b; Xiao et al., 2007; Figure 3; Table 2).
Increased carcinogenesis was associated with increased perme-
ability, local production of pro-inflammatory mediators, such as
prostaglandin E2, inflammatory cytokines and chemokines, and
expression of genes involved in cell survival and proliferation (Bcl-
xL and Cyclin D1) downstream of NF-κB. Gut epithelial cells
played a pivotal role in mediating the regulatory functions of
TIR8/SIGIRR, since TIR8/SIGIRR overexpression in gut epithe-
lium rescued Tir8/Sigirr-deficient mice from developing severe
CAC (Xiao et al., 2007). Studies with mice deficient of TLRs,
ILRs, MyD88, or Tir8/Sigirr suggest that a fine balance of pro-
and anti-inflammatory signals induced by commensal bacteria
through TLRs- or ILRs-signaling is necessary for the homeostatic
regulation of colon epithelium proliferation and apoptosis as well
as for inflammatory responses, mechanisms of repair, and colitis-
associated tumorigenesis (Rakoff-Nahoum et al., 2004; Araki et al.,
2005; Salcedo et al., 2010). In the AOM-DSS CAC model, mucosal
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damage induced by DSS causes exposure to commensal micro-
biota and enhanced migration of bacteria to the mesenteric lymph
nodes (Vaishnava et al., 2008). Thus, in this model,Tir8/Sigirr plays
a protective role probably by modulating the levels of TLRs signal-
ing in the epithelial cells directly through its interaction with the
TLRs that are activated by commensal bacteria. However, the con-
trol on pathways activated by TLRs signaling and involving ILRs
can not be excluded. In addition, mediators downstream of NF-
κB, such as IL-6, which has been shown to promote cancer growth
in inflammation-associated cancer models through STAT3 acti-
vation, and chemokines, which promote leukocyte recruitment
and angiogenesis in gastrointestinal neoplasia (Karin, 2006), were
increased in Tir8/Sigirr-deficient mice treated with AOM and DSS.
The role of Tir8/Sigirr was recently investigated in the Apcmin/+
model, a spontaneous intestinal cancer model mimicking the
Familial Adenomatous Polyposis syndrome, where loss of het-
erozygosity (LOH) of the tumor suppressor Apc is the exclusive
genetic alteration leading to the tumor initiation in the Apcmin/+
mouse (Yamada et al., 2002). Akt-mTOR signaling is a critical
pathway driving tumor initiation in the Apcmin/+ mouse, since it
promotes cell cycle progression through posttranscriptional con-
trol of the key cell cycle regulators, such as Cyclin D1, cyclin
E, and c-Mycand LOH of Apc (Aoki et al., 2003). Xiao et al.
(2010) found that Tir8/Sigirr-deficiency in the Apcmin/+ mouse
led to increased microadenoma formation, resulting in sponta-
neous colonic polyposis. Tir8/Sigirr-deficiency was associated with
increased Akt-mTOR signaling and tumor initiation through its
impact on cell proliferation and LOH of Apc in epithelium. This
phenotype was dependent on the presence of commensal bac-
teria in the gut, implicating a critical role of TLRs signaling in
colonic tumorigenesis in Apcmin/+ mice; however, hyperactiva-
tion of mTOR was also observed upon stimulation of epithelial
cells with IL-1. Thus, this study suggests that Tir8/Sigirr is a tumor
suppressor that controls colonic tumorigenesis by inhibiting IL-
1- and TLRs-induced mTOR-mediated cell cycle progression and
consequent genetic instability (Xiao et al., 2010).
ROLE OF TIR8/SIGIRR IN CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL) is the most frequent
leukemia in the western world and accounts for about 40% of all
leukemias in adults over the age of 65 years. CLL is characterized
by the accumulation of CD5+ monoclonal B-cells in primary and
secondary lymphoid tissues. Over time and because of unknown
molecular events CLL may progress into an aggressive form char-
acterized by a prolymphocytoid transformation; small cells are
gradually replaced by clonally related, larger elements (prolym-
phocytes). Genetic defects are involved in the pathogenesis of the
disease including repeated mutations in the MyD88, XPO1, and
NOTCH1 genes (Puente et al., 2011; Rossi et al., 2012). Further-
more, stimuli originating from the microenvironment appear to
contribute to the selection and expansion of the malignant clone
(Ghia and Caligaris-Cappio, 2006) and CLL is emerging as a pro-
totype of cancers where both genetic and micro environmental
factors concur to the development, expansion and progression of
the disease (Muzio et al., 2009a,b). Both normal and leukemic
human B-cells express detectable levels of TIR8/SIGIRR mRNA
(Muzio et al., 2009b); however, by PCR array analysis, malignant
B-cells appeared to have low levels of mRNA (Arvaniti et al., 2011).
Nevertheless, since protein levels of TIR8/SIGIRR may be differen-
tially regulated (Veliz Rodriguez et al., 2012), it will be important
to analyze TIR8/SIGIRR expression on the cell surface of normal
and leukemic B-cells. As regarding to mouse models, an analysis
was performed in TCL1 transgenic animals, a well characterized
mouse model of CLL (Bichi et al., 2002). Both total and CD19+
enriched splenocytes expressed detectable Tir8/Sigirr mRNA levels
that were significantly lower in CD19+ cells from TCL1 trans-
genic mice. Moreover, peritoneal B1 cells (which are marked by
CD5 expression) expressed lower levels of Tir8/Sigirr mRNA com-
pared with splenic B-cells suggesting that an intrinsic program
of CD5+ B-cells may regulate Tir8/Sigirr expression (Bertilaccio
et al., 2011).
To address the functional involvement of TIR8/SIGIRR in CLL,
Tir8/Sigirr was genetically inactivated in the TCL1 transgenic
mouse model (Bertilaccio et al., 2011). The absence of Tir8/Sigirr
did not modify normal B cell populations in wild type mice.
In contrast, lack of Tir8/Sigirr in TCL1 transgenic mice accel-
erated appearance of monoclonal B-cell expansions and mouse
life span was shortened. The morphology and phenotype of the
mouse leukemic expansions reproduced the progression of human
CLL into an aggressive phase characterized by the appearance of
prolymphocytes (Bertilaccio et al., 2011; Figure 3; Table 2). Over-
all, these observations suggest an inhibitory role of TIR8/SIGIRR
in CLL onset and progression. However, it is not clear whether
TIR8/SIGIRR exerts its activity directly onto the malignant clone
or indirectly through the tumor microenvironment, and which
molecular mechanisms are involved. Indeed, different TLRs lig-
ands can lead to either proliferation (TLR2, TLR4, TLR9; Tarnani
et al., 2010), apoptosis (TLR3 and TLR9; Liang et al., 2010), or
chemoresistance (TLR7 and TLR8; Cherfils-Vicini et al., 2010)
of different cancer cells (Rakoff-Nahoum and Medzhitov, 2009).
Examples of endogenous TLRs or ILRs ligands, which could con-
stitutively activate cognate membrane receptors in the malignant
clone or cells of the tumor microenvironment in the absence
of TIR8/SIGIRR, are ILRs family cytokines such as IL-1, IL-18,
IL-33, and TLRs ligands including PAMPs derived from intesti-
nal microflora and/or DAMPs containing autoantigens. Thus, this
study shows that unabated TLRs and/or ILRs stimulation is func-
tionally involved in the development and progression of CLL, and
that TIR8/SIGIRR plays a non-redundant role in controlling this
process.
CONCLUDING REMARKS
Interleukin-1R like receptors and TLRs are key inflammatory
receptors involved in inflammation and immunity recognizing IL-
1 family ligands released in several conditions including sterile
inflammation and cell death, or PAMPs and DAMPs, respec-
tively. Available information is consistent with the view that
TIR8/SIGIRR is a conserved and broadly expressed negative reg-
ulator of inflammation, tissue damage, autoimmunity, and cancer
(Figure 3; Table 2), acting by negatively regulating ILRs- or TLRs-
dependent signaling, possibly by interfering with the recruit-
ment of TIR domain containing signaling molecules (Figure 2).
Although TIR8/SIGIRR is still considered an orphan receptor, IL-
36Ra has been proposed as brain-specific TIR8/SIGIRR ligand,
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and the possibility of other TIR8/SIGIRR recognizing molecule(s)
cannot be dismissed.
Members of the ILR family have been involved in T cell
polarization and proliferation (Chan et al., 2001; Neighbors
et al., 2001; Schmitz et al., 2005; Acosta-Rodriguez et al., 2007)
and TIR8/SIGIRR has emerged as a negative regulator affect-
ing Th1, Th2, and Th17 differentiation, which play a major
role in autoimmunity and sterile inflammation (Garlanda et al.,
2004, 2007b; Xiao et al., 2007; Bozza et al., 2008; Bulek et al.,
2009).
Thus, strong genetic evidence in mice is consistent with a
non-redundant regulatory function of TIR8/SIGIRR in pathogen-
dependent as well as sterile inflammation, innate immunity,
and polarized adaptive responses. Data supporting its relevance
to human disease are still scarce, however, preliminary genetic
evidence in humans and gene expression studies support the
hypothesis that TIR8/SIGIRR could play a regulatory function
also in human inflammatory conditions.
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